OptimizeRx Corp Q1 2025 10-Q Filed

Ticker: OPRX · Form: 10-Q · Filed: May 13, 2025 · CIK: 1448431

Optimizerx CORP 10-Q Filing Summary
FieldDetail
CompanyOptimizerx CORP (OPRX)
Form Type10-Q
Filed DateMay 13, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, financials, quarterly-report

TL;DR

OptimizeRx Q1 2025 10-Q is in. Financials look stable.

AI Summary

OptimizeRx Corp filed its 10-Q for the period ending March 31, 2025. The filing details financial information for the first quarter of 2025, including changes in common stock, treasury stock, additional paid-in capital, and retained earnings. The company's fiscal year ends on December 31st.

Why It Matters

This filing provides investors with the latest financial snapshot of OptimizeRx Corp, crucial for understanding the company's performance and financial health in early 2025.

Risk Assessment

Risk Level: low — This is a routine quarterly financial filing with no immediate red flags.

Key Numbers

Key Players & Entities

FAQ

What were the specific changes in OptimizeRx Corp's Additional Paid-In Capital during the first quarter of 2025?

The filing indicates that Additional Paid-In Capital changed from $103,949,000 as of December 31, 2024, to $104,129,000 as of March 31, 2025.

How did OptimizeRx Corp's Retained Earnings change from the end of 2024 to the end of Q1 2025?

Retained Earnings increased from $10,973,000 as of December 31, 2024, to $11,310,000 as of March 31, 2025.

What was the value of OptimizeRx Corp's Common Stock as of March 31, 2025?

As of March 31, 2025, the value of Common Stock was $1,000.

Did OptimizeRx Corp have any Treasury Stock as of March 31, 2025?

Yes, OptimizeRx Corp had $1,000 in Treasury Stock as of March 31, 2025.

What is the business address for OptimizeRx Corp?

The business address for OptimizeRx Corp is 260 Charles Street, Suite 302, Waltham, MA 02453.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding OptimizeRx Corp (OPRX).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing